ArticleToxicological sciences : an official journal of the Society of Toxicology2025
Advanced cardiotoxicity profiling using field potential imaging with UHD-CMOS-MEA in human iPSC-derived cardiomyocytes.
Article in Toxicological sciences : an official journal of the Society of Toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Accurate assessment of cardiotoxicity using human induced pluripotent stem cell (iPSC)-derived cardiomyocytes is critical for ensuring drug safety during preclinical development. However, existing in vitro methodologies predominantly focus on QT interval prolongation and arrhythmia risk, often lacking the capacity to capture the complex interplay among multiple ion channels or to detect early manifestations of chronic cardiotoxicity-both of which are essential for evaluating long-term cardiac safety. Moreover, reliable prediction of pharmacological mechanisms of action remains a significant challenge. In this study, we employed field potential imaging utilizing an ultra-high-density complementary metal-oxide-semiconductor microelectrode array (MEA) comprising 236,880 electrodes distributed across a 5.9 × 5.5 mm active area. With 91.9% surface coverage by 11 μm electrodes spaced at 0.25 μm, the platform achieves near single-cell resolution across the entire cardiomyocyte monolayer. This system enabled the extraction of high-resolution electrophysiological endpoints, including the number and spatial variability of excitation origins, conduction velocity, and propagation area-thereby extending the analytical capabilities beyond those of conventional MEAs. Pharmacological testing revealed compound-specific alterations: Isoproterenol increased excitation origins, mexiletine reduced conduction velocity, and E-4031 diminished propagation area. Although these agents are well characterized, their effects were visualized with unprecedented spatiotemporal resolution, reflecting their underlying mechanisms of action. Multivariate analysis incorporating both conventional and novel endpoints enabled accurate classification of mechanisms under acute conditions. Furthermore, chronic cardiotoxicity induced by low-dose doxorubicin (0.03 μM) was sensitively detected within 24 h-earlier and at lower concentrations than previously reported-based on significant reductions in conduction velocity and propagation area. Collectively, these findings establish a high-resolution, mechanism-aware framework for in vitro cardiotoxicity profiling, offering improved predictive accuracy by capturing multi-ion channel interactions, spatial conduction abnormalities, and early signs of chronic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.